



Performance of at-home self-collected saliva and nasal-oro-pharyngeal swabs in the surveillance of COVID-19

Paulo H. Braz-Silva , Ana C. Mamana , Camila M. Romano , Alvina C. Felix , Anderson V. de Paula , Noeli E Ferreira , Lewis F. Buss , Tania R. Tozetto-Mendoza , Rafael A. V. Caixeta , Fabio E. Leal , Regina M. Z. Grespan , João C. S. Bizário , Andrea B. C. Ferraz , Dipak Sapkota , Simone Gianecchini , Kelvin K. To , Alain Doglio & Maria C. Mendes-Correa

To cite this article: Paulo H. Braz-Silva , Ana C. Mamana , Camila M. Romano , Alvina C. Felix , Anderson V. de Paula , Noeli E Ferreira , Lewis F. Buss , Tania R. Tozetto-Mendoza , Rafael A. V. Caixeta , Fabio E. Leal , Regina M. Z. Grespan , João C. S. Bizário , Andrea B. C. Ferraz , Dipak Sapkota , Simone Gianecchini , Kelvin K. To , Alain Doglio & Maria C. Mendes-Correa (2021) Performance of at-home self-collected saliva and nasal-oro-pharyngeal swabs in the surveillance of COVID-19, Journal of Oral Microbiology, 13:1, 1858002

To link to this article: <https://doi.org/10.1080/20002297.2020.1858002>



© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 09 Dec 2020.



Submit your article to this journal [↗](#)






View related articles [↗](#)



View Crossmark data [↗](#)

Performance of at-home self-collected saliva and nasal-oro-pharyngeal swabs in the surveillance of COVID-19

Paulo H. Braz-Silva ^{a,b}, Ana C. Mamana^a, Camila M. Romano^a, Alvina C. Felix^a, Anderson V. de Paula^a, Noeli E. Ferreira^a, Lewis F. Buss^a, Tania R. Tozetto-Mendoza ^a, Rafael A. V. Caixeta^b, Fabio E. Leal^c, Regina M. Z. Grespan^c, João C. S. Bizário^c, Andrea B. C. Ferraz^c, Dipak Sapkota^d, Simone Giannecchini^e, Kelvin K. To ^{f,g,h}, Alain Doglioⁱ and Maria C. Mendes-Correa^a

^aLaboratory of Virology (LIM-52), Institute of Tropical Medicine of São Paulo, School of Medicine, University of São Paulo, São Paulo, Brazil; ^bDepartment of Stomatology, School of Dentistry, University of São Paulo, São Paulo, Brazil; ^cDepartment of Medicine, Municipal University of São Caetano do Sul, São Caetano do Sul, Brazil; ^dDepartment of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway; ^eDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy; ^fState Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li KaShing Faculty of Medicine of the University of Hong Kong, Special Administrative Region, China; ^gDepartment of Microbiology, Queen Mary Hospital, Hong Kong Special Administrative Region, China; ^hDepartment of Clinical Microbiology and Infection Control, The University of Hong Kong – Shenzhen Hospital, Shenzhen, China; ⁱLaboratory MICORALIS (Microbiologie Orale, Immunité Et Santé) School of Dentistry, University of Côte d'Azur, Nice, France

ABSTRACT

Background: SARS-CoV-2 quickly spreads in the worldwide population, imposing social restrictions to control the infection, being the massive testing another essential strategy to break the chain of transmission.

Aim: To compare the performance of at-home self-collected samples – saliva and combined nasal-oro-pharyngeal swabs (NOP) – for SARS-CoV-2 detection in a telemedicine platform for COVID-19 surveillance.

Material and methods: We analyzed 201 patients who met the criteria of suspected COVID-19. NOP sampling was combined (nostrils and oropharynx) and saliva collected using a cotton pad device. Detection of SARS-CoV-2 was performed by using the Altona RealStar[®] SARS-CoV-2 RT-PCR Kit 1.0.

Results: There was an overall significant agreement (κ coefficient value of 0.58) between saliva and NOP. Considering results in either sample, 70 patients positive for SARS-CoV-2 were identified, with 52/70 being positive in NOP and 55/70 in saliva. This corresponds to sensitivities of 74.2% (95% CI; 63.7% to 83.1%) for NOP and 78.6% (95% CI; 67.6% to 86.6%) for saliva.

Conclusion: Our data show the feasibility of using at-home self-collected samples (especially saliva), as an adequate alternative for SARS-CoV-2 detection. This new approach of testing can be useful to develop strategies for COVID-19 surveillance and for guiding public health decisions.

ARTICLE HISTORY

Received 23 October 2020

Revised 24 November 2020

Accepted 27 November 2020

KEYWORDS



Saliva; coronavirus; PCR; primary health care; infection control; telemedicine

Introduction

Rapid and accurate diagnostic tests are essential for controlling the SARS-CoV-2 pandemic. Nevertheless, biological specimen collection is an important logistic challenge to provide massive testing [1–3]. The possibility to use self-collected samples for COVID-19 testing offers several advantages, especially to minimize the risk of exposing health-care workers to the virus, since self-collection does not require direct involvement of trained personnel in the sample collection [4,5]. Recently, publications have been shown a similar sensitivity between saliva samples and nasal swabs collected by health-care workers and those collected by a patient for COVID-19 molecular diagnosis, thus providing an important background for the choice of this strategy for surveillance of COVID-19 [6–8].

Saliva sampling has been described as a good alternative for SARS-CoV-2 detection, showing additional advantages compared to swab collection [9–12]. Saliva collection does not cause discomfort or nasal bleeding to patients and does not require swab collectors or personal protective equipment, which are currently in short-supply in the market [3]. In addition, saliva allows examination of several biomarkers, which could be useful as molecular signatures for patient stratification regarding infection severity [10,13,14].

In a pandemic scenario, at-home self-collection of samples plays a key role in the surveillance and control of the infection by allowing the patient with clinical suspicion of COVID-19 to have access to proper healthcare and quick isolation of the confirmed cases [4,5]. Recently published studies show that 80–85% of individuals infected with SARS-CoV

CONTACT Paulo H. Braz-Silva  pbraz@usp.br  Laboratório de Virologia - Instituto de Medicina Tropical de São Paulo, FMUSP, São Paulo 05403-000, Brazil

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

-2 have few or no symptoms, while 15–20% develop more severe disease, often associated with advanced age or other co-morbidities [15].

The Corona São Caetano program is a primary care initiative providing specific home care to all residents of São Caetano do Sul, state of São Paulo, Brazil. This program started in April 2020 due to the increasing number of COVID-19 cases in the country. Self-collection of nasal-oro-pharyngeal swabs has been used to obtain samples for diagnosis since the beginning of the epidemics, with excellent results, as the hospitalization rate was less than 3% among the patients enrolled in the program [16].

The aim of this study was to compare the performance of two different at-home self-collected samples – saliva and combined nasal-oro-pharyngeal swabs (NOP) – for COVID-19 molecular diagnosis in the community patients outside the health-care facilities.

Patients and methods

The present study was developed in a telemedicine platform for COVID-19 surveillance called ‘Corona São Caetano’. Residents of the municipality aged 12 years or older who had suspected symptoms were encouraged to contact the program via a website or by phone. They were invited to complete a screening questionnaire including socio-demographic data, information on type, onset and duration of the symptoms.

In the last two weeks of May 2020, a series of 201 consecutive patients participating in the program were included in the present study. The patients met the defined criteria of suspected COVID-19 (i.e., having at least two of the following symptoms: fever, cough, sore throat, coryza, change in/loss of smell [anosmia] or/and taste [ageusia]; or one of these symptoms plus at least two other symptoms consistent with COVID-19) were further evaluated. These patients were then called by a health-care professional in order to complete a risk assessment. All pregnant women and patients meeting pre-defined screening criteria for severe disease were advised to attend a hospital service. All the other patients were offered a home visit for self-collection of saliva and NOP samples.

Patients testing RT-PCR positive for SARS-CoV-2 were followed up for 14 days (a maximum of 7 phone calls) after completion of their initial questionnaire, whereas those who tested negative were followed up in the primary health-care program. The patients were asked to contact the platform for a new consultation if they developed new symptoms.

This study was conducted according to ethical standards defined by institutional and national research ethics committees and the Helsinki Declaration of 1964, including subsequent amendments or

comparable ethical standards, and approved by the Clinics Hospital Research Ethics Committee of the University of São Paulo School of Medicine under protocol number 3.979.632. Informed consent was obtained from all the individuals enrolled in this study.

Sample collection

NOP sampling were combined (both nostrils and oropharynx) using commercial flocked swabs with plastic applicators (Goodwood medical care Ltd., Jinzhou, China). Saliva samples were collected using a cotton pad device – Salivette™ (Sarstedt AG & CO. KG, Nümbrecht, Germany). In order to provide guidance on self-collection procedures, a link to an instructional video was sent to each participant before the home visit. Briefly, patients were instructed to use the swabs in both nostrils and posterior region of the mouth and put both swabs into a tube containing saline solution. For saliva collection, they were instructed to chew carefully a cotton pad for one minute and put it into a specific tube. The samples were collected during the morning hours and the participants were instructed to avoid eating, drinking or toothbrushing at least one hour before the saliva collection. In accordance with the Corona São Caetano Program procedures, samples were immediately put in a cool box (2–8°C) and stored at 4°C in a refrigerator until shipment to the lab by a specialized carrier in the afternoon the same day.

RNA extraction and real-time PCR

To recover the saliva from the devices, the tubes were centrifuged at 5,000 g for 5 minutes. Total nucleic acid was extracted from 200 µl of the saline solution containing NOP and recovered saliva by using the NucliSENS EasyMag (BioMérieux, Durham, NC) automated DNA/RNA extraction platform.

Detection of SARS-COV-2 RNA was performed by using the Altona RealStar® SARS-CoV-2 RT-PCR Kit 1.0 (Altona Diagnostics GmbH, Hamburg, Germany) which employs a B-COV specific probe directed to the *E* gene and a SARS-COV-2-specific probe directed to the *S* gene. Results were considered positive when one or both genes were amplified with a cycle threshold (Ct) <40.

Statistical analyses

Cohen’s kappa coefficient (κ) was used to measure the agreement between RT-PCR-based detection of SARS-COV-2 in saliva and NOP swabs. The sensitivity of each method was calculated assuming that positive cases in either sample type represented true positives, with 95% confidence intervals being calculated by using the exact method.

Next, we defined four analytic groups as follows: NOP-/saliva- (G1); NOP-/saliva+ (G2); NOP+/saliva- (G3); NOP+/saliva+ (G4). In order to identify clinical features associated with positivity in NOP and saliva, we specifically compared groups G2 to G4, G3 to G4, and G2 to G3. We used chi-squared test and Wilcoxon's rank-sum test to compare clinical features (i.e. age, gender, symptoms and onset of illness) between the patients in these groups.

We then explored the relationship between the RT-PCR cycle threshold (Ct) and the sample type. We first analyzed group G4 (NOP+/saliva+) and assessed the association between Ct values by using the simple linear regression. Differences in the distribution of Ct values using NOP and saliva were assessed with paired Wilcoxon's rank-sum test. We also assessed the association between time from symptom onset and collection of saliva and NOP by using the simple linear regression. Statistical significance was set at 0.05. All analyses were performed by using the R Statistical Software, version 3.6.3.

Results

For the current study, 201 consecutive patients participating in the Corona São Caetano program and who met the suspected COVID-19 case definition were included. RT-PCR-based COVID-19 testing was performed in samples from NOP and saliva and the results are shown in Table 1.

Overall, 16.4% (33/201) of the results were discordant giving a moderate agreement between both the sampling methods with a Cohen's kappa coefficient of 0.58. Overall, assuming that positive test results in either sample type represent true infections around 35% of patients (n = 70) were identified to be positive with COVID-19, while 26% (n = 52) and 27% (n = 55) were positive based on NOP or saliva

Table 1. Comparison of SARS-CoV-2 RNA status in saliva and NOP samples in 201 patients undergoing testing for COVID-19.

NOP	Saliva	
	Negative	Positive
Negative	131	18
Positive	15	37

detection, respectively. This corresponds to sensitivities of 74.2% (95% CI; 63.7% to 83.1%) for NOP and 78.6% (95% CI; 67.6% to 86.6%) for saliva samples. Of note, 9% (N = 18) and 7% (N = 15) resulted in saliva or NOP single positives, respectively.

Associations between clinical features and SARS-CoV-2 positivity in saliva and NOP samples using RNA RT-PCR

To investigate the relationship between SARS-CoV-2 status in NOP and saliva and demographic and clinical features, the patients were categorized in four groups (G1 to G4) (Table 2); NOP and saliva SARS-CoV-2 negative patients were grouped in G1 (NOP-/saliva-, n = 131); NOP-/saliva+ patients in G2 (N = 18); NOP+/saliva- in G3 (n = 15) and NOP+/saliva+ in G4 (N = 37). We did not find any significant relationship regarding the demographic data of patients in the different groups, although the sex ratio may be different in G2 as compared to G4. Also, no significant correlation was found regarding clinical symptoms; only ageusia appeared to be more prevalent in patients with positivity of SARS-CoV-2 in NOP (P = 0.028). Interestingly, the delay between clinical symptoms onset and time of sample collection was significantly shorter (P < 0.05) in G4 as compared to G2 and G3, suggesting that patients with simultaneous SARS-CoV-2 positivity in NOP and saliva (G4-patients) were more prompt to quickly display clinical symptoms (Table 2).

Table 2. Demographic and clinical characteristics of 201 patients with suspected COVID-19 tested with RT-PCR in both saliva and NOP samples.

	NOP-/saliva- (G1)	NOP-/saliva+ (G2)	NOP+/saliva- (G3)	NOP+/saliva+ (G4)	P-value G3 vs. G4	P-value G2 vs. G4
	N = 131 n(%) or median (IQR)	N = 18 n(%) or median (IQR)	N = 15 n(%) or median (IQR)	N = 37 n(%) or median (IQR)		
Age	40 (31–52)	30 (29–49)	32 (26–44)	39 (30–48)	0.312	0.907
Gender						
Male	49 (62)	2 (11)	5 (33)	18 (48.6)	0.484	0.016
Female	81 (38)	16 (89)	10 (67)	19 (51.4)		
Delay between symptoms and collection (days)	6 (4–9)	6 (5–9)	7 (5–8)	4 (4–6)	0.039	0.029
Symptoms						
Fever	43 (33)	6 (33)	7 (47)	19 (51)	1.0	0.332
Anosmia	37 (28)	8 (44)	11 (79)	18 (53)	0.188	0.996
Ageusia	38 (29)	7 (39)	11 (73)	13 (35)	0.028	1.0
Nasal congestion	73 (56)	11 (61)	10 (67)	29 (78)	0.60	0.30
Coryza	76 (58)	7 (39)	5 (33)	19 (51)	0.38	0.56
Myalgia	88 (68)	12 (66)	9 (60)	26 (70)	0.697	0.10
Arthralgia	62 (48)	9 (50)	7 (47)	19 (51)	1.0	1.0
Cough	97 (75)	12 (66)	11 (73)	30 (81)	0.80	0.314

Notes: NOP- naso/oropharyngeal swab; G1 – group 1; G2 – group 2; G3 – group 3; G4 – group 4; IQR – interquartile range.

RT-PCR cycle thresholds in saliva and NOP samples

In order to investigate the relationship between the RT-PCR cycle threshold (Ct) and sample type (saliva or NOP), we first compared the Ct values from G4 (NOP+/saliva+, $n = 37$) and assessed the association between Ct values using simple linear regression. We found a strong correlation between the Ct values in saliva and naso/oropharyngeal samples (Figure 1). The coefficients of the regression lines (β) were 0.79 ($P < 0.001$) and 0.74 ($P = 0.002$) for *E* and *S* genes, respectively. A β -coefficient < 1 indicated that, in patients with SARS-CoV-2 positivity in NOP and saliva (G4), Ct values tended to be higher in saliva than in NOP (also see Figure 2(a)).

Next, we compared the Ct values between the groups G3 (NOP+/saliva-) and G4 (NOP+/saliva+). It was observed that the Ct values were lower in patients positive in both NOP and saliva samples (median [IQR], 21.5 [19–27]) compared to those positive only in NOP samples (29 [25–33], $P = 0.01$, Wilcoxon's rank-sum test) for the *E* gene. Moreover, these results were also found for the *S* gene (Figure 2(b)).

Relationship between timing of sample collection and SARS-CoV-2 detection

Because timing of sample collection is a critical parameter of SARS-CoV-2 diagnosis, we further investigated the possible relationship between NOP and saliva SARS-CoV-2 detection and the delay between clinical symptom onset and timing of sample collection. Although the Ct values tended to be higher at later periods from the onset of symptoms, this did not reach statistical significance (Figure 3).

Discussion

We prospectively analyzed a cohort of patients with mild symptoms of COVID-19 to assess the diagnostic performance of at-home self-collection of combined naso-oropharyngeal swabs (NOP) and saliva samples.

According to our data, there was an overall significant agreement (κ coefficient value of 0.58) between the performances of saliva and NOP samples in the diagnosis of COVID-19. Assuming that positive results in either sample type represent true infections, a total of 70 patients positive for SARS-CoV-2 were identified, with 52/70 being positive in NOP and 55/70 in saliva. This corresponds to sensitivities of 74.2% (95% CI; 63.7% to 83.1%) for NOP and 78.6% (95% CI; 67.6% to 86.6%) for saliva samples. We also found a strong correlation (β -coefficients < 1) between the cycle threshold (Ct) values in saliva and NOP samples. However, the Ct values for the studied genes tended to be higher in saliva than in NOP samples.

The use of saliva to detect SARS-CoV-2 has been extensively analyzed by different authors, showing that saliva can be used as an alternative sample to nasopharyngeal swabs for COVID-19 molecular diagnosis [9,10]. The sensitivity found in their studies varied from 81% to 100% [11,12,17–21]. The majority of the studies were conducted with hospitalized patients presenting more severe clinical forms of the disease, or patients attending a health-care unit. It is important to highlight that even with a different population and different saliva collection (i.e. cotton pad device), we found similar sensitivity values.

To the best of our knowledge, the present study is the first one in the literature to prospectively examine the performance of at-home self-collected saliva and NOP, in a telemedicine-based platform for COVID-19 surveillance. This is highly desirable in a pandemic scenario as it contributes to minimizing the risk of infection transmission in these settings. Additionally, it significantly reduces the workload burden of the health-care units.

In our study for around 16% of the patients, the RT-PCR results gave discordant results between both sampling methods. This good overlap between both specimen types was in line with other studies where in general the agreement rate observed varied from 0.45 to 1 [11,22]. This variation in agreement may be associated with different factors, such as clinical characteristics of the population, diagnostic kits, saliva




Figure 1. Comparison of RT-PCR cycle thresholds between naso-oropharyngeal and saliva samples in 37 patients with positive results in both samples. The coefficients of the regression lines are 0.79 ($P < 0.001$) for gene *E* and 0.74 ($P = 0.002$) for gene *S*.




Figure 2. (a/b) – Violin plots showing the distribution of cycle thresholds in nasal-oropharyngeal swabs (NOP) and saliva samples for the two genes (*E* and *S*) amplified by RT-PCR. Boxplots shows median, interquartile range and range as standard. Analysis of the 37 patients with positive results in both sample types by comparing the distributions of cycle thresholds between NOP and saliva samples. Paired Wilcoxon's rank-sum test was used, in which *P*-values were <0.001 for genes *E* and *S*. (c/d) – Distribution of SARS-CoV-2 RT-PCR cycle thresholds in the 52 positive nasal-oropharyngeal swabs (NOP) samples stratified by RT-PCR results in saliva (NOP+/saliva- versus NOP+/saliva+). Boxplots shows median, interquartile range and range as standard. Distributions were compared by using paired Wilcoxon's rank-sum test, in which *P*-values were 0.21 and 0.35 for genes *E* and *S*, respectively.

collection methods, among others. However, these inconsistent results are likely to be related to the fact the virus can reach the oral and nasopharyngeal area with different kinetics being not always present at the same time in both sites as previously reported [23].

It has been postulated that there is a minimum of three different pathways for SARS-CoV-2 to reach the saliva: firstly, from the lower and upper respiratory tract; secondly, presence in the blood and gingival crevicular fluid; and thirdly, through salivary gland infection, with subsequent release of viral particles into the saliva via salivary ducts [10,24,25]. It is believed that the highest viral concentration observed in saliva is derived from the respiratory tract [12]. Therefore, the finding of viruses in saliva would be expected only in cases with a higher viral load, since

the viral particles observed in the saliva also depend on the amount of viruses coming from the respiratory tract. However, the fact that in our study 9% of the samples were positive in saliva in absence of NOP positivity could be indicative that at least in a minority part the virus has salivary origin.

When we compared the cases positive in both methods to those positive in NOP only, it was found that Ct values were lower in the first group. This finding reinforces the idea that the viral load has to be higher (lower Ct) in order to be positive in the saliva. Clearly, according to our results, the viral load influenced the results. Only cases with a higher viral load (lower Ct) were positive in both methods, whereas cases with higher Ct values were positive in NOP samples only.




Figure 3. Relationship between illness course (i.e. time elapsed between symptom onset and sample collection) and cycle threshold values for nasal-oro-pharyngeal swabs (NOP) (left-hand panels) and saliva samples (right-hand panels). In the NOP samples, the regression coefficients for cycle threshold (delay of \log_2 -days) for genes *E* and *S* were 0.5 ($P = 0.72$) and 1.1 ($P = 0.42$), respectively; the regression coefficients for saliva samples were 0.04 ($P = 0.98$) and -0.26 ($P = 0.87$) for genes *E* and *S*, respectively.

Some studies have compared the viral load between nasopharyngeal swab and saliva samples, showing a tendency for a higher viral load (or lower Cts) in nasopharyngeal swabs [10,19]. The severity of the cases included and the time elapsed between collection of material and onset of symptoms are essential information to interpret correctly these results, since the sensitivity of the diagnostic methods varies according to these variables.

When we compared the chance of identifying the virus in saliva and NOP samples in relation to the time interval between onset of symptoms and sample collection time, it was observed that the identification of the virus in both samples was associated with a shorter interval of time. These results stress the importance of early diagnosis of COVID-19, in which a sample should be collected within the first days of symptoms, thus minimizing the loss of sensitivity of the molecular diagnosis [26]. Different

studies have analyzed the SARS-CoV-2 shedding in different biologic specimens, reporting that viral loads from upper respiratory tract samples peak within a week of symptom onset and follow a relatively consistent downward trajectory [27]. The viral load in other biologic specimens, including saliva, follows the same trajectory [28]. However, according to these studies, the viral load does not seem to be as high as that observed in respiratory tract samples. Therefore, our findings are in line with these observations.

Chemosensory deficits associated with SARS-CoV-2 infection are quite frequent among patients with mild or moderate disease, considered a very early symptom. Interestingly, in our study ageusia was the only symptom statistically associated with patients SARS-CoV-2 positive only in NOP samples (G3; $P = 0.028$). These results corroborate with the role of the neurotropic and neuro-invasive characteristics

of coronaviruses in the pathogenesis of ageusia, more than a local infection of the gustatory buds [29]. However, the small number of patients in each group is an important limitation to this analysis.

Recent studies comparing samples collected by specialized health-workers and self-collected by the patients for COVID-19 molecular diagnosis showed that both methods had similar sensitivity, which highlights the reliability of self-collection as a public health strategy for COVID-19 surveillance [6–8]. Our results corroborated these findings as they showed that both self-collected samples had good sensitivity, especially the saliva, with 78.6% (95% CI; 67.6% to 86.6%).

The present study showed that self-collection of saliva and NOP for diagnosis of COVID-19 is feasible in the studied population. Given the similar sensitivities of saliva and NOP samples for detection of SARS-CoV-2 in patients with mild symptoms, it is expected that self-collection of either sample can be valuable in the surveillance of COVID-19 at a population level [30]. Moreover, by simplifying the procedure and, above all, avoiding the need for the patient to go to a specialized laboratory, this innovative approach can improve COVID-19 diagnosis, notably allowing the sample to be collected as soon as possible after appearance of the first symptoms. However, in this sense, the ease of collection and feasibility for examination of molecular biomarkers for disease stratification and prognosis justify the use of self-collected saliva as a preferred biological sample [2,26].

As the main limitation of this study, we could mention the non-inclusion of asymptomatic individuals in the platform of COVID-19 surveillance.

In conclusion, our data show the possibility of using at-home self-collected samples (especially saliva), as an adequate alternative for SARS-CoV-2 detection. This new approach of testing can be useful to develop strategies for COVID-19 surveillance and for guiding public health decisions.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was supported by the Laboratórios de Investigação Médica - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo.

ORCID

Paulo H. Braz-Silva  <http://orcid.org/0000-0002-1842-9521>

Tania R. Tozetto-Mendoza  <http://orcid.org/0000-0002-5659-1052>

Kelvin K. To  <http://orcid.org/0000-0002-1921-5824>

References

- [1] Landry ML, Criscuolo J, Peaper DR. Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients. *J Clin Virol.* 2020;130:104567.
- [2] Yokota I, Shane PY, Okada K, et al. Mass screening of asymptomatic persons for SARS-CoV-2 using saliva. *Clin Infect Dis.* 2020. DOI:10.1093/cid/ciaa1388
- [3] Ott IM, Strine MS, Watkins AE, et al. Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices. *medRxiv.* 2020. DOI:10.1101/2020.08.03.20165233
- [4] Hall EW, Luisi N, Zlotorzynska M, et al. Willingness to use home collection methods to provide specimens for SARS-CoV-2/COVID-19 research: survey study. *J Med Internet Res.* 2020;22:e19471.
- [5] Valentine-Graves M, Hall E, Guest JL, et al. At-home self-collection of saliva, oropharyngeal swabs and dried blood spots for SARS-CoV-2 diagnosis and serology: post-collection acceptability of specimen collection process and patient confidence in specimens. *PLoS One.* 2020;15:e0236775.
- [6] Therschlens JH, von Buchwald C, Koch A, et al. Self-collected versus healthcare worker-collected swabs in the diagnosis of severe acute respiratory syndrome coronavirus 2. *Diagnostics (Basel).* 2020;10(9):678. DOI:10.3390/diagnostics10090678.
- [7] Tu YP, Jennings R, Hart B, et al. Swabs collected by patients or health care workers for SARS-CoV-2 testing. *N Engl J Med.* 2020;383:494–496.
- [8] Hanson KE, Barker AP, Hillyard DR, et al. Self-collected anterior nasal and saliva specimens versus healthcare worker-collected nasopharyngeal swabs for the molecular detection of SARS-CoV-2. *J Clin Microbiol.* 2020;58. DOI:10.1128/JCM.01824-20.
- [9] Fernandes LL, Pacheco VB, Borges L, et al. Saliva in the diagnosis of COVID-19: a review and new research directions. *J Dent Res.* 2020;99:1435–1443.
- [10] Sapkota D, Soland TM, Galtung HK, et al. COVID-19 salivary signature: diagnostic and research opportunities. *J Clin Pathol.* 2020;jclinpath-2020-206834. DOI:10.1136/jclinpath-2020-206834
- [11] Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. *N Engl J Med.* 2020;383:1283–1286.
- [12] To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis.* 2020;20:565–574.
- [13] Henrique Braz-Silva P, Pallos D, Giannecchini S, et al. SARS-CoV-2: what can saliva tell us? *Oral Dis.* 2020. DOI:10.1111/odi.13365
- [14] Adeoye J, Thomson P. ‘The double-edged sword’ – an hypothesis for Covid-19-induced salivary biomarkers. *Med Hypotheses.* 2020;143:110124.
- [15] Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science.* 2020;368:489–493.
- [16] Leal FE, Mendes-Correa MC, Buss LF, et al. A primary care approach to the COVID-19 pandemic: clinical features and natural history of 2,073 suspected cases in the Corona Sao Caetano programme, Sao Paulo, Brazil. *medRxiv.* 2020. DOI:10.1101/2020.06.23.20138081.
- [17] Pasomsub E, Watcharananan SP, Boonyawat K, et al. Saliva sample as a non-invasive specimen for the diagnosis

- of coronavirus disease 2019: a cross-sectional study. *Clin Microbiol Infect.* 2020. DOI:10.1016/j.cmi.2020.05.001
- [18] To KK, Tsang OT, Yip CC, et al. Consistent detection of 2019 novel coronavirus in saliva. *Clin Infect Dis.* 2020;71:841–843.
- [19] Williams E, Bond K, Zhang B, et al. Saliva as a noninvasive specimen for detection of SARS-CoV-2. *J Clin Microbiol.* 2020;58(8):e00776-20.
- [20] Azzi L, Carcano G, Gianfagna F, et al. Saliva is a reliable tool to detect SARS-CoV-2. *J Infect.* 2020;81:e45–e50.
- [21] Cheuk S, Wong Y, Tse H, et al. Posterior oropharyngeal saliva for the detection of SARS-CoV-2. *Clin Infect Dis.* 2020. DOI:10.1093/cid/ciaa797
- [22] Jamal AJ, Mozafarihashjin M, Coomes E, et al.; Toronto Invasive Bacterial Diseases Network C-I. Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis.* 2020. DOI:10.1093/cid/ciaa848
- [23] Rao M, Rashid FA, Sabri F, et al. Comparing nasopharyngeal swab and early morning saliva for the identification of SARS-CoV-2. *Clin Infect Dis.* 2020. DOI:10.1093/cid/ciaa1156
- [24] Xu J, Li Y, Gan F, et al. Salivary glands: potential reservoirs for COVID-19 asymptomatic infection. *J Dent Res.* 2020;99:989.
- [25] Kheir S, Kheir M, Gupta AA, et al. Is the gingival sulcus a potential niche for SARS-Corona virus-2? *Med Hypotheses.* 2020;143:109892.
- [26] Nagura-Ikeda M, Imai K, Tabata S, et al. Clinical evaluation of self-collected saliva by quantitative reverse transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcription-loop-mediated isothermal amplification, and a rapid antigen test to diagnose COVID-19. *J Clin Microbiol.* 2020;58(9):e01438-20.
- [27] Weiss A, Jellingsso M, Sommer MOA. Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: a systematic review and meta-analysis. *EBioMedicine.* 2020;58:102916.
- [28] Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ.* 2020;369:m1443.
- [29] Samaranayake LP, Fakhruddin KS, Panduwawala C. Sudden onset, acute loss of taste and smell in coronavirus disease 2019 (COVID-19): a systematic review. *Acta Odontol Scand.* 2020;78:467–473.
- [30] Wehrhahn MC, Robson J, Brown S, et al. Self-collection: an appropriate alternative during the SARS-CoV-2 pandemic. *J Clin Virol.* 2020;128:104417.